Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Assessing Changes In Berkshire Hathaway Holdings

19h seekingalpha
Some major changes in holdings occurred at Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) in its investment portfolio over the latest quarter. Today we will expose the changes and rate those purchases and sales with our Friedrich algorithm. (407-6)

Amgen: Outlook

23h seekingalpha
Amgen (AMGN) is one of the major biotechnology and pharmaceutical companies. Revenue in 2017 was $22.85 billion. Non-GAAP net income in 2017 was $9.25 billion and non-GAAP EPS was $12.58. (264-0)

United Therapeutics (UTHR) Q4 Earnings Decline on High Costs

2018-02-22 zacks
United Therapeutics Corporation (UTHR - Free Report) reported adjusted earnings of $3.89 per share in the fourth quarter of 2017, which declined 4.2% from the year-ago quarter due to higher operating costs. The Zacks Consensus Estimate was pegged at $1.94 per share. (135-0)

Middlemen Play Gatekeeper in Battle to Curb Soaring Drug Costs - Bloomberg

2018-02-22 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (347-1)

Teva's Problems Continue to Mount With No Relief in Sight

2018-02-21 zacks
Israel-based drugmaker, Teva Pharmaceutical Industries Limited (TEVA - Free Report) is in a major mess right now. The question now is how will the world’s largest generic maker recover? (266-1)

Invest Like Warren Buffett With These ETFs

2018-02-20 zacks
Following investing strategies of billionaire investor Warren Buffett is everyone’s dream. Buffett’s Berkshire Hathaway Inc. (BRK.B - Free Report) has added more than 100% over the last five years (as of February 15, 2018), way better than the 73% gain of the broader market ETF SPDR S&P 500 ETF (SPY - Free Report) during the same time frame. (165-1)

How Amazon Could Lose Its Healthcare Bid While Drug Distributor Stocks Win

2018-02-19 seekingalpha
Amazon.com (NASDAQ:AMZN) has been one of the most innovative and disruptive companies of this century, with incredible success in areas that lie outside of what has been historically perceived as its core business (book selling). (557-3)

Valeant: Generic Syprine Is Finally Here

2018-02-19 seekingalpha
Hits to Syprine and Cuprimine could hurt sentiment for VRX. LOE for Apriso and Uceris tablets could be on the horizon. (129-0)

You May Not Want To Follow Buffett Out Of Phillips 66

2018-02-18 seekingalpha
Berkshire Hathaway announced that they had reached an agreement with Phillips 66 wherein the business would buy back $3.3 billion of its own stock from Berkshire. (329-1)

TEVA / Teva Pharmaceutical Industries Ltd. S-3/A

2018-02-17 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333-222767       SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-3     Amendment No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter and translation of registrant’s name into English)       Israel    N/A (State or other jurisdiction of incorporation or o

TEVA / Teva Pharmaceutical Industries Ltd. S-3/A

2018-02-17 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333-222767       SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-3     Amendment No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter and translation of registrant’s name into English)       Israel    N/A (State or other jurisdiction of incorporation or o

TEVA / Teva Pharmaceutical Industries Ltd. S-3/A

2018-02-17 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333-222767       SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-3     Amendment No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter and translation of registrant’s name into English)       Israel    N/A (State or other jurisdiction of incorporation or o

TEVA / Teva Pharmaceutical Industries Ltd. S-3/A

2018-02-17 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333-222767       SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-3     Amendment No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter and translation of registrant’s name into English)       Israel    N/A (State or other jurisdiction of incorporation or o

TEVA / Teva Pharmaceutical Industries Ltd. S-3/A

2018-02-17 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333-222767       SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-3     Amendment No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter and translation of registrant’s name into English)       Israel    N/A (State or other jurisdiction of incorporation or o

TEVA / Teva Pharmaceutical Industries Ltd. S-3/A

2018-02-17 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on February 16, 2018 Registration No. 333-222767       SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM S-3     Amendment No. 1 to REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter and translation of registrant’s name into English)       Israel    N/A (State or other jurisdiction of incorporation or o


TEVA : Teva Pharmaceutical Industries Stock Analysis and Research Report

Teva Pharmaceutical Industries is global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic medicines and a focused portfolio of specialty medicines. The company operate worldwide, with a significant presence in the United States, Europe and many other markets around the world. Its key strengths include itsworld-leading generics expertise and portfolio, focused specialty portfolio, robust R&D capabilities, global infrastructure and scale and dedicated leadership and employees.

Teva Pharmaceutical believe company is strategically positioned to benefit from market, economic and regulatory trends in global healthcare. These trends include aging populations, the increasing prevalence of chronic diseases, economic pressure on governments and private payors to provide affordable healthcare solutions, legislative and regulatory reforms, scientific and technological advances, increased patient awareness...

Click for full article
CUSIP: 881624209